Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-094-0 | CAS number: 68515-51-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 5.61 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
- Explanation for the modification of the dose descriptor starting point:
- There is no repeated dose inhalation data. For this substance it is unlikely that the toxicological profile is route dependent. Therefore the repeated dose oral data has been used. 1,2-Benzenedicarboxylic acid, di-C8-10-alkylesters is expeted to be rapidly absorbed from the gastro-intestinal tract, means 100 %, no data exist for the inhalative absorption, therefore as worst case 100 % is expected, whereas dermal absorption is expected to be slower. However, because no exact absorption factors are available, in conclusion it is expected that the absoption factors for all routes are 100 %. That means an overestimation of the dermal DNELs. That means also an additional AF for route-to-route is not required.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not tpyically applied in the derivation of an inhalation DNEL
- AF for other interspecies differences:
- 2.5
- Justification:
- Default value
- AF for intraspecies differences:
- 5
- Justification:
- worker
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.8 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 80 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- There is no repeated dose dermal data. For this substance it is unlikely that the toxicological profile is route dependent. Therefore the repeated dose oral data has been used. 1,2-Benzenedicarboxylic acid, di-C8-10-alkylesters is expeted to be rapidly absorbed from the gastro-intestinal tract, means 100 %, whereas dermal absorption is expected to be slower. However, because no exact absorption factors are available, in conclusion it is expected that the absoption factors for all routes are 100 %. That means an overestimation of the dermal DNELs. That means also an additional AF for route-to-route is not required.
- AF for dose response relationship:
- 1
- Justification:
- starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 5
- Justification:
- worker
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
The most appropriate endpoint for derivation of a DNEL is the rat oral NOAEL of 79.6 mg/kg bw/d with the read-across substance 1,2-Benzenedicarboxylic acid, di-C8-10-alkyl esters taken from a well conducted subchronic toxicity study (liver weight effects). Based on the acute toxicity data, DNELs do not need to be derived for local or systemic effects for the worker population since the material has a low potential for acute toxicity.
Worker long term exposure - systemic effects (dermal and inhalation) DNELs were calculated from the NOAEL, assuming a 100% dermal absorption rate (worst case). The value was divided by an adjustment factor of 100 according to REACH TGD (exposure duration factor of 2, interspecies factor of 10, and intraspecies (worker population) factor of 5), leading to a DNEL of 0.8 mg/kg/d.
The corrected worker inhalation starting point was the corrected NOAEC of 140.3 mg/m3 and was derived from the oral NOAEL of 79.6 mg/kg/d by multiplying by the inverse of the standard respiratory volume of the rat during an 8 hour period (2.63) and multiplied by the ratio of standard respiratory volume for humans to the 8 hour worker standard respiratory volume (0.67). The corrected starting point was adjusted by a factor of 25 (interspecies factor of 2.5, intraspecies factor (worker) of 5, and exposure duration of 2), resulting in a calculated DNEL of 5.61 mg/m3.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1.386 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 69.3 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- There is no repeated dose inhalation data. For this substance it is unlikely that the toxicological profile is route dependent. Therefore the repeated dose oral data has been used. 1,2-Benzenedicarboxylic acid, di-C8-10-alkylesters is expeted to be rapidly absorbed from the gastro-intestinal tract, means 100 %, no data exist for the inhalative absorption, therefore as worst case 100 % is expected, whereas dermal absorption is expected to be slower. However, because no exact absorption factors are available, in conclusion it is expected that the absoption factors for all routes are 100 %. That means an overestimation of the dermal DNELs. That means also an additional AF for route-to-route is not required.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Not tpyically applied in the derivation of an inhalation DNEL
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.4 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 80 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- There is no repeated dose dermal data. For this substance it is unlikely that the toxicological profile is route dependent. Therefore the repeated dose oral data has been used. 1,2-Benzenedicarboxylic acid, di-C8-10-alkylesters is expeted to be rapidly absorbed from the gastro-intestinal tract, means 100 %, whereas dermal absorption is expected to be slower. However, because no exact absorption factors are available, in conclusion it is expected that the absoption factors for all routes are 100 %. That means an overestimation of the dermal DNELs. That means also an additional AF for route-to-route is not required.
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.4 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 80 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- it is the same route
- AF for dose response relationship:
- 1
- Justification:
- Starting point is a NOAEL
- AF for differences in duration of exposure:
- 2
- Justification:
- subchronic to chronic
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- rat to human
- AF for other interspecies differences:
- 2.5
- Justification:
- default value
- AF for intraspecies differences:
- 10
- Justification:
- General population
- AF for the quality of the whole database:
- 1
- Justification:
- good quality
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The most appropriate endpoint for derivation of a DNEL is the rat oral NOAEL of 79.6 mg/kg bw/d (ca. 80 mg/kg bw/d) with the read-across substance 1,2-Benzenedicarboxylic acid, di-C8-10-alkyl esters taken from a well conducted subchronic toxicity study (liver weight effects). Based on the acute toxicity data, DNELs do not need to be derived for local or systemic effects for the general population since the material has a low potential for acute toxicity.
General population long term exposure - systemic effects (oral, dermal and inhalation) DNELs were calculated from the NOAEL, assuming a 100% dermal absorption rate (worst case). The value was divided by an adjustment factor of 200 (exposure duration factor of 2, interspecies factor of 10, and intraspecies (general population) factor of 10), leading to a DNEL of 0.4 mg/kg/d.
The corrected general population inhalation starting point was the corrected NOAEC of 69.3 mg/m3 and was derived from the oral NOAEL of 79.6 mg/kg/d by multiplying by the inverse of the standard respiratory volume of the rat during a 24 hour period (0.87). The corrected starting point was adjusted by a factor of 50 (interspecies factor of 2.5, intraspecies factor (general population) of 10, and exposure duration of 2), resulting in a calculated DNEL of 1.39 mg/m3.
The general population oral starting point is 79.6 mg/kg/d (ca. 80 mg/kg bw/d). An adjustment factor of 200 is applied (interspecies factor of 10, intraspecies factor (general population) of 10, and exposure duration of 2), leading to a DNEL of 0.4 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.